GALAPAGOS NV/S (GLPG) Expected to Announce Earnings of -$0.65 Per Share

Analysts expect GALAPAGOS NV/S (NASDAQ:GLPG) to announce earnings per share (EPS) of ($0.65) for the current quarter, Zacks reports. Two analysts have issued estimates for GALAPAGOS NV/S’s earnings, with the lowest EPS estimate coming in at ($1.22) and the highest estimate coming in at $0.40. GALAPAGOS NV/S reported earnings of ($0.85) per share during the same quarter last year, which suggests a positive year over year growth rate of 23.5%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, October 23rd.

On average, analysts expect that GALAPAGOS NV/S will report full-year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.94) to ($1.87). For the next fiscal year, analysts anticipate that the business will post earnings of ($3.91) per share, with EPS estimates ranging from ($4.64) to ($3.24). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for GALAPAGOS NV/S.

Several equities analysts have recently commented on GLPG shares. Zacks Investment Research cut shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research report on Wednesday. ValuEngine upgraded shares of GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 28th. BidaskClub cut shares of GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a research report on Tuesday, May 1st. Morgan Stanley boosted their target price on shares of GALAPAGOS NV/S from $126.00 to $127.00 and gave the company an “overweight” rating in a research report on Monday, August 6th. Finally, Royal Bank of Canada dropped their target price on shares of GALAPAGOS NV/S to $94.00 and set a “sector perform” rating for the company in a research report on Friday, June 29th. Four analysts have rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $109.00.

GALAPAGOS NV/S traded down $4.79, hitting $108.26, during midday trading on Friday, Marketbeat.com reports. The company’s stock had a trading volume of 45,920 shares, compared to its average volume of 80,168. GALAPAGOS NV/S has a 1-year low of $81.44 and a 1-year high of $121.09.

Several institutional investors have recently made changes to their positions in the stock. Employees Retirement System of Texas grew its holdings in shares of GALAPAGOS NV/S by 26.8% during the 2nd quarter. Employees Retirement System of Texas now owns 71,000 shares of the biotechnology company’s stock valued at $6,545,000 after purchasing an additional 15,000 shares during the last quarter. Federated Investors Inc. PA grew its holdings in shares of GALAPAGOS NV/S by 9.3% during the 2nd quarter. Federated Investors Inc. PA now owns 1,424,763 shares of the biotechnology company’s stock valued at $131,335,000 after purchasing an additional 121,415 shares during the last quarter. Stanley Laman Group Ltd. bought a new stake in shares of GALAPAGOS NV/S during the 2nd quarter valued at approximately $720,000. Provident Investment Management Inc. bought a new stake in shares of GALAPAGOS NV/S during the 2nd quarter valued at approximately $249,000. Finally, Alps Advisors Inc. grew its holdings in shares of GALAPAGOS NV/S by 7.7% during the 2nd quarter. Alps Advisors Inc. now owns 73,389 shares of the biotechnology company’s stock valued at $6,765,000 after purchasing an additional 5,234 shares during the last quarter. 17.34% of the stock is currently owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply